A study presented at Digestive Disease Week revealed insulin-stimulating treatments including incretin mimetics were not associated with an increased risk of pancreatic adenocarcinoma in diabetes patients. However, researchers said longer-term studies are needed to further assess the drugs' effect, as incretin mimetics have only been available for less than 10 years whereas pancreatic cancer develops over 18 years.

Related Summaries